About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Wearable Gait Sensors | Clinical Trials | Clareo Health

Back to clinical trial search

Active Not RecruitingNCT06628934

Wearable Gait Sensors

This research study is testing body-worn sensors to measure movement during simple tests of coordination, in order to evaluate the progression and severity of Spinocerebellar ataxia.

Lead sponsor: University of Chicago•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Chicago

Study participants will complete a neurological exam with sensors (iSARA exam) and three patient-reported questionnaires (PROM-Ataxia, ABC Scale, EQ-5D-5L). Participation will take about an hour.

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Ataxia Group - Individuals who have a genetic-confirmation of SCA diagnosis and are able to sit or stand unassisted for 30 seconds and follow directions.
•Healthy Control Group - Individuals who are able to sit or stand unassisted for 30 seconds and follow directions.

Exclusion Criteria

•Any other neurological or musculoskeletal disorder not attributed to the SCA that could affect balance, gait or voluntary movement.

Related studies

RECRUITINGPhase 1

Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

NCT06672445 · Spinocerebellar Ataxia Type 2

RECRUITINGPhase 3

A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene

NCT07185347 · Spinocerebellar Ataxia 27B (SCA27B)

RECRUITINGPhase 1/2

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

NCT05822908 · Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, and more

Effects of Oral Administration of Antrodia Cinnamomea Products for Clinical Symptoms in Spinocerebellar Ataxia Patients

NCT06633003 · Spinocerebellar Ataxia

The EUROSCA Natural History Study

NCT02440763 · Spinocerebellar Ataxia

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 5, 2026Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

Phase—

Enrollment600

Start dateJun 2017

Last updatedFeb 5, 2026

Condition

Spinocerebellar Ataxia

Locations shown

University of Chicago

Chicago, Illinois

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 5, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions